Low-Dose vs High-Dose Drug-Coated Balloon for Symptomatic Femoropopliteal Artery Disease
JACC: Cardiovascular Interventions · 2023-11 · 16 (21) · 2655-2665
DOI: 10.1016/j.jcin.2023.08.022 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2023-11. Verfasst von Tatsuya Nakama und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Tokyo Bay Medical Center, Urayasu, Japan; Division of Vascular Surgery, Department of Surgery, Jikei University School of M…. Hauptthemen laut MEDLINE: Angioplasty, Balloon, Cardiovascular Agents, Peripheral Arterial Disease. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Randomized trials have shown comparable outcomes between second-generation low-dose drug-coated balloons (LD-DCBs) and first-generation high-dose drug-coated balloons (HD-DCBs); but the trial patients had low clinical complexity, and there were no comparisons in medically complex populations. OBJECTIVES: The aim of this study was to compare outcomes between an LD-DCB (Ranger; 2.0 μg/mm2) and an HD-DCB (IN.PACT; 3.5 μg/mm2) in patients with symptomatic femoropopliteal artery disease. METHODS: PROSPECT MONSTER (Prospective Comparison of Second-Generation Low-Dose Drug-Coated Balloon With High-Dose Drug-Coated Balloon) was a prospective, multicenter, nonrandomized trial that prospectively collected data from 581 patients who underwent endovascular therapy with the LD-DCB (n = 370) or the HD-DCB (n = 211) for symptomatic femoropopliteal artery disease (Rutherford classes 2-5). The primary outcome was the 1-year primary patency of the LD-DCB in comparison with that of the HD-DCB, as evaluated using propensity score matching. The incidence of impaired flow after drug-coated balloon application was also evaluated. RESULTS: Propensity score matching extracted 163 pairs (358 and 163 patients in the LD-DCB and HD-DCB groups, respectively), with no significant intergroup difference in baseline characteristics. The 1-year primary patency rates in the matched population were similar between the LD-DCB and HD-DCB groups (87.0% [95% CI: 82.5%-91.7%] vs 81.3% [95% CI: 74.8%-88.5%]; HR: 0.93; 95% CI: 0.55-1.59; P = 0.79), as was the incidence of impaired flow (13.6% vs 9.8%; OR: 1.46; 95% CI: 0.78-2.73; P = 0.24). No baseline characteristics had any significant interaction effects on the association of the LD-DCB vs the HD-DCB and 1-year restenosis risk. CONCLUSIONS: LD-DCBs demonstrate efficacy and safety comparable with HD-DCBs in patients with complex clinical backgrounds, suggesting that drug-coated balloon treatment using a lower dose may be possible.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Tokyo Bay Medical Center, Urayasu, Japan; Division of Vascular Surgery, Department of Surgery, Jikei University School of Medicine, Tokyo, Japan. Electronic address: tatsuya_nakama@med.miyazaki…
- Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
- Department of Cardiology, Heart & Vascular Institute, Funabashi Municipal Medical Center, Funabashi, Japan.
- Department of Cardiology, Tokyo Saiseikai Central Hospital, Tokyo, Japan.
- Department of Cardiology, Shonan Kamakura General Hospital, Kamakura, Japan.
- Department of Cardiovascular Medicine, Asahi General Hospital, Asahi, Japan.
Zitieren
APA
Nakama, T., Takahara, M., Iwata, Y., Suzuki, K., Tobita, K., Hayakawa, N., Horie, K., Mori, S., Obunai, K., Ohki, T., & PROSPECT MONSTER Study Investigators (2023). Low-Dose vs High-Dose Drug-Coated Balloon for Symptomatic Femoropopliteal Artery Disease. JACC: Cardiovascular Interventions, 16(21), 2655-2665. https://doi.org/10.1016/j.jcin.2023.08.022
Vancouver
Nakama T, Takahara M, Iwata Y, Suzuki K, Tobita K, Hayakawa N, et al. Low-Dose vs High-Dose Drug-Coated Balloon for Symptomatic Femoropopliteal Artery Disease. JACC: Cardiovascular Interventions. 2023;16(21):2655-2665. doi:10.1016/j.jcin.2023.08.022
BibTeX
@article{Nakama2023,
author = {Nakama, Tatsuya and Takahara, Mitsuyoshi and Iwata, Yo and Suzuki, Kenji and Tobita, Kazuki and Hayakawa, Naoki and Horie, Kazunori and Mori, Shinsuke and Obunai, Kotaro and Ohki, Takao and PROSPECT MONSTER Study Investigators, PROSPECT MONSTER Study Investigators},
title = {Low-Dose vs High-Dose Drug-Coated Balloon for Symptomatic Femoropopliteal Artery Disease},
journal = {JACC: Cardiovascular Interventions},
year = {2023},
volume = {16},
number = {21},
pages = {2655--2665},
doi = {10.1016/j.jcin.2023.08.022}
}
EUVIMED